Pyrazine functionalized Ag(I) and Au(I)-NHC complexes are potential antibacterial agents

Current Medicinal Chemistry

Volumn 19, Issue 24, 2012, Pages 4184-4193

  Roymahapatra, G ^a   Mandal, S M ^b   Porto, W F ^c   Samanta, T ^a   Giri, S ^b   Dinda, J ^a   Franco, O L ^c   Chattaraj, P K ^b  

^a HALDIA INSTITUTE OF TECHNOLOGY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY   (India)

^c UCB PHARMA   (Belgium)

Author keywords

Ag(I) and Au(I) NHC complexes; Antibacterial activity; Biofilm eradication; CDFT; Peptidoglycan layer

Indexed keywords

1 METHYL 3 PYRIMIDINECHLORIDE; 2,6 BIS [1 METHYLIMIDAZOL 2 YL] PYRAZINECHLORIDE; AMPICILLIN; ANTIBIOTIC AGENT; CARBENE; CHLORAMPHENICOL; CHLORO[2,6 BIS(1 METHY IMIDAZOL)PYRAZINE]SILVER; CHLORO[2,6 BIS(1 METHYL IMIDAZOL)PYRAZINE]GOLD; CIPROFLOXACIN; GOLD COMPLEX; STREPTOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BIOFILM; BLOOD COMPATIBILITY; DRUG POTENCY; DRUG SYNTHESIS; ESCHERICHIA COLI; FLOW CYTOMETRY; MEMBRANE PERMEABILITY; MOLECULAR DOCKING; NONHUMAN; STREPTOCOCCUS MUTANS;

ANTI-BACTERIAL AGENTS; BINDING SITES; BIOFILMS; COORDINATION COMPLEXES; GOLD; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HETEROCYCLIC COMPOUNDS; METHANE; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; PEPTIDOGLYCAN; PYRAZINES; SILVER;

EID: 84866656627     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802430090     Document Type: Article

References (68)

1. Sharma, A. Antimicrobial resistance: No action today, no cure tomorrow. Ind. J. Med. Microbiol. 2011, 29, 91-92.
2. Bourissou, D.; Guerret, O.; Gabbai F. P.; Bertrand, G. Stable Carbenes. Chem. Rev. 2000, 100, 39-91.
3. de Fremont, P.; Marion, N.; Nolan, S. P. Carbenes: Synthesis, properties, and organometallic chemistry. Coord. Chem. Rev. 2009, 253, 862-893.
4. Canac Y.; Soleilhavoup M.; Conejero S.; Bertrand G.J. Stable non-Nheterocyclic carbenes (non-NHC): recent progress. J. Organomet. Chem. 2004, 689, 3857-3865.
5. Melaimi M.; Soleilhavoup M.; Bertrand G. Stable cyclic carbenes and related species beyond diaminocarbenes. Angew. Chem. Int. Ed. 2010, 49, 8810-8849.
6. Schuster O.; Yang L.; Raubenheimer H. G.; Albrecht M. Beyond conventional N-heterocyclic carbenes: abnormal, remote, and other Classes of NHC ligands with reduced heteroatom stabilization. Chem. Rev. 2009, 109, 3445-3478.
7. Ofele K.; Tosch E.; Taubmann C.; Herrmann W. A.; Carbocyclic carbene metal complexes. Chem. Rev. 2009, 109, 3408-3444.
8. Wanzlick H. W. Aspects of nucleophilic carbene chemistry. Angew. Chem. Int. Ed. Engl. 1962, 1, 75-80.
9. Wanzlick H. W.; Schonherr H. J. Direct synthesis of a mercury salt-carbene complex. Angew. Chem, Int. Ed. Engl. 1968, 7, 141-142.
10. Arduengo A. J. III ; Harlow R. L. ; Kline M. A. A Stable crystalline carbene. J. Am. Chem. Soc. 1991, 113, 361-363.
11. Peris E.; Crabtree R.H. Recent homogeneous catalytic applications of chelate and pincer N-heterocyclic carbenes. Coord. Chem. Rev. 2004, 248, 2239-2246.
12. Crudden C. M.; Allan D.P. Stability and reactivity of N-heterocyclic carbene complexes. Coord. Chem. Rev. 2004, 248, 2247-2273.
13. Puch D.; Danopoulos A. A. Metal complexes with 'pincer'-type ligands incorporating N-heterocyclic carbene functionalities. Coord. Chem. Rev. 2007, 251, 610-641.
14. Adhikary S. D.; Samanta T.; Roymahapatra G.; Loiseau F.; Jouvenot D.; Dinda J. Synthesis, structure and electrochemical behaviour of Ru(II)-and Pt(II)-carbene complexes of the NCN-pincer1,3-bis(2-pyridylmethyl)- 1Hbenzimidazolium chloride. New J. Chem. 2010, 34, 1974-1980.
15. Hahn F. E.; Jahnke M. C.; Heterocyclic carbenes: synthesis and coordination chemistry. Angew. Chem. 2008, 47, 3122-3172.
16. Marion N.; González S. D.; Nolan S. P. N-heterocyclische carbene also organokatalysatoren. Angew. Chem. 2007, 119, 3046-3058.
17. Wang H. M. J.; Lin I. J. B. Facile synthesis of silver(I)-carbene complexes. Useful carbene transfer agents. Organometallics. 1998, 17, 972-975.
18. Russel, A. D.; Path, F. R.; Hugo, W. B.; Antimicrobial activity and action of silver. Prog. Med. Chem. 1994, 31, 351-370.
19. Landsdown, A. B. G. A review of the use of silver in wound care: facts and fallacies. Br. J. Nursing. 2004, 13, S6-S19.
20. Landsdown, A. B. G. Bacterial resistance to silver in wound care and medical devices. J. Wound Care. 2007, 16, 15-19.
21. Blodgett, R. C.; Heuer, M. A.; Pietrusko, R. G. Auranofin: a unique oral chrysotherapeutic agent. Semin. Arth. Rheum. 1984, 255-273.
22. Chaffman, M.; Brogden, R. N.; Heel, R. C.; Speight, T. M. ; Avery, G. S. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid Arthritis. Drugs. 1984, 27, 378-424.
23. McKeage, M. J.; Maharaj, L.; Berners-Price, S. J. Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria. Coord. Chem.Rev. 2002, 232 ,127-135.
24. Rigobello, M. P.; Scutari, G.; Folda A.; Bindoli A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem. Pharmacol. 2004, 67, 689-696.
25. Rigobello, M. P.; Scutari, G.; Boscolo, R.; Bindoli, A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br. J. Pharmacol. 2002, 136, 1162-1168.
26. Lillo, V.; Mas-Marzá, E.; Segarra, A. M.; Carbó, J. J.; Bo, C.; Peris, E.; Fernandez, E. Palladium-NHC complexes do catalyse the diboration of alkenes: mechanistic insights Chem. Commun. 2007, 3380-3382.
27. Loch, J. A.; Albrecht, M.; Peris, E.; Mata, J.; Faller, J. W.; Crabtree, R. H. Palladium complexes with tridentate pincer bis-carbene ligands as efficient catalysts for C-C coupling. Organometallics, 2002, 21, 700-706.
28. Stephan, M.; Goetz, B.; Richard, F.; Tobias, S. Patent No. DE102008022788, Application No. DE2008-102008022788, Dated. 2008-05-08.
29. Hindi, K. M.; Panzner, M. J.; Tessier, C. A.; Cannon, C. L.; Youngs, W. J. The Medicinal Applications of Imidazolium Carbene-Metal Complexes. Chem. Rev. 2009, 109, 3859-3884.
30. Panzner, M. J.; Hindi, K. M.; Wright, B. D.; Taylor, J. B.; Han, D. S.; Youngs, W. J.; Cannon, C. L. A theobromine derived silver N-heterocyclic carbene: synthesis, characterization, and antimicrobial efficacy studies on cystic fibrosis relevant pathogens. Dalton Trans. 2009, 35, 7308-7313.
31. Patil, S.; Deally, A.; Gleeson, B.; Müller-Bunz, H.; Paradisi, F.; Tacke, M. Novel benzyl-substituted N-heterocyclic carbene-silver acetate complexes: synthesis, cytotoxicity and antibacterial studies. Metallomics. 2011, 3, 74-88.
32. Hindi, K.M.; Siciliano, T. J.; Durmus, S.; Panzner, M. J.; Medvetz, D. A.; Reddy, D. V.; Hogue, L. A.; Hovis, C. E.; Hilliard, J. K.; Mallet, R. J.; Tessier, C. A.; Cannon, C. L.; Youngs, W. J. Synthesis, stability, and antimicrobial studies of electronically tuned silver acetate N-Heterocyclic carbenes. J. Med. Chem. 2008, 51, 1577-1583.
33. Samantaray, M. K.; Katiyar, V.; Pang, K.; Nanavati, H.; Ghosh, P. Silver Nheterocyclic carbene complexes as initiators for bulk ring-opening polymerization (ROP) of l-lactides. J. Organometallic Chem. 2007, 692, 1672-1682.
34. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement Document M100-S17. CLSI, Wayne, PA: CLSI. 2007.
35. Mandal, S. M.; Pati, B. R.; Das, A. K.; Ghosh, A. K. Characterization of a symbiotically effective Rhizobium resistant to arsenic: Isolated from the root nodules of Vigna mungo (L.) Hepper grown in an arsenic-contaminated field. J. Gen. Appl. Microbiol. 54, 2008, 93-99.
36. Croes, S.; Deurenberg, R. H.; Boumans, M. L.; Beisser, P. S.; Neef, C.; Stobberingh E. E. Staphylococcus aureus biofilm formation at the physiologic glucose concentration depends on the S. aureus lineage. BMC Microbiol. 2009, 9, 229.
37. Coenye, T.; Honraet, K.; Rigole, P.; Nadal Jimenez, P.; Nelis, H. J. In vitro Inhibition of Streptococcus mutans Biofilm Formation on Hydroxyapatite by Subinhibitory Concentrations of Anthraquinones. Antimicrob. Agents Chemother. 2007, 51, 1541.
38. Jarosz, L. M.; Deng, D. M.; van der Mei, H. C.; Crielaard, W.; Krom, B. P. Streptococcus mutans competencestimulating peptide inhibits Candida albicans hypha formation. Eukaryot. Cell. 2009, 8, 1658.
39. Olson, M. E.; Ceri, H.; Morck, D. W.; Buret, A. G.; Read, R. R. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can. J. Veter. Res. 2002, 66, 86.
40. Mandal, S. M.; Migliolo, L.; Franco, O. L.; Ghosh, A. K. Identification of an antifungal peptide from Trapa natans fruits with inhibitory effects on Candida tropicalis biofilm formation. Peptides. 2011, 32, 1741.
41. Parr, R. G.; Donnelly, R. A.; Levy, M.; Palke, W. E. Electronegativity: The density functional viewpoint. J. Chem. Phys. 1978, 68, 3081-3807.
42. Parr, R. G.; Pearson, R. G. Absolute hardness: companion parameter to absolute electronegativity. J. Am. Chem. Soc. 1983, 105, 7512-7516.
43. Pearson, R. G. Chemical Hardness: Applications from Molecules to Solids; Wiley-VCH: Weinheim, 1997.
44. Chattaraj, P. K., Sarkar, U.; Roy, D. R. Electrophilicity Index. Chem. Rev. 2006, 106, 2065-2091
45. Chattaraj, P. K.; Roy, D. R. Update 1 of: Electrophilicity Index. Chem. Rev. 2007, 107, PR46-PR74
46. Chattaraj, P. K.; Giri, S.; Duley, S. Update 2 of: Electrophilicity Index. Chem. Rev. 2011, 111, PR43-PR75.
47. Gaussian 03, Revision E.01; Gaussian, Inc., Wallingford CT, 2004.
48. Parthasarathi, R.; Padmanabhan, J.; Subramanian, V.; Maiti, B.; Chattaraj, P. K. Chemical reactivity profiles of two selected polychlorinated biphenyl. J. Phys. Chem. A 2003, 107, 10346-10352.
49. Arulmozhiraja, S.; Selvin, P. C.; Fujiti, T. Structures, potential energy curves, and torsional barrier heights for selected polychlorinated biphenyls: A Density Functional Theory Study. J. Phys. Chem. A. 2002, 106, 12376-12385.
50. Cho, S.; Wang, Q.; Swaminathan, C. P.; Hesek, D.; Lee, M.; Boons, G. J.; Mobashery, S.; Mariuzza, R. A. Structural insights into the bactericidal mechanism of human peptidoglycan recognition proteins. Proc. Natl. Acad. Sci. U S A. 2007, 104, 8761.
51. Delano Scientific, LLC .The PyMol molecular graphics system, Version 1.2. http://www.pymol.org.
52. Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput. Chem. 2010, 31, 455-461.
53. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009, 30, 2785-2791.
54. Peris, E.; Loch, J. A.; Mata, J.; Crabtree, R. H.; A Pd complex of a tridentate pincer CNC bis-carbene ligand as a robust homogenous Heck catalyst, Chem. Commun. 2001, 201-202.
55. Nielsen, D. J.; Cavell, K. J.; Skelton, B. W.; White, A. H.; Inorg. Chim. Acta. 2002, 327, 116-125.
56. Recchia, G. D.; Hall, R. M. Gene cassettes: a new class of mobile element. Microbiology, 1995, 141, 3015-3027.
57. Briñas, L.; Zarazaga, M.; Sáenz, Y.; Ruiz-Larrea, F.; Torres, C. Betalactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrob. Agents Chemother. 2002, 46, 3156-3163.
58. Evers, S.; Courvalin, P. Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583. J Bacteriol. 1996, 178,1302-1309.
59. Shaw, W.V.; Bentley, D.W.; Sands, L. Mechanism of chloramphenicol resistance in Staphylococcus epidermidis. J. Bacteriol. 1970, 104, 1095-1105.
60. Morita, Y.; Kodama, K.; Shiota, S.; Mine, T.; Kataoka, A.; Mizushima, T.; Tsuchiya T. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob. Agents Chemother. 1998, 42, 1778-1782.
61. Research on microbial biofilms PA-03-047, NIH , National Heart Lung and Blood Institute. 2002, 12.
62. Li, W. R.; Xie, X. B.; Shi, Q. S.; Zeng, H. Y.; Ou-Yang, Y. S.; Chen, Y. B. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl. Microbiol. Biotechnol. 2009, 85, 1115-1122.
63. Sondi, I.; Salopek-Sondi, B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J. Colloid Interface Sci. 2004, 275, 177-182.
64. Fung, M. C.; Bowen, D. L. Silver products for medical indications: riskbenefit assessment. J Toxicol. Clin. Toxicol. 1996, 34, 119-126.
65. Ge, M.; Chen, Z.; Onishi, H. R.; Kohler, J.; Silver, L. L.; Kerns, R.; Fukuzawa, S.; Thompson, C.; Kahne, D. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala., D-Ala-D-Ala. Science. 1999, 284, 507-511.
66. Xie, J.; Pierce, J. G.; James, R. C.; Okano, A.; Boger, D. L. A Redesigned vancomycin engineered for dual d-Ala-d-Ala and d-Ala-d-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria. J. Am. Chem. Soc., 2011, 133, 13946-13949.
67. Parthasarathi, R. ; Padmanabhan, J. ; Subramanian, V.; Maiti, B.; Chattaraj, P. K. J. Phys. Chem. A 2003, 107, 10346.
68. Arulmozhiraja, S.; Selvin, P.C.; Fujiti, T. J. Phys. Chem. A 2002, 106, 1765.